Read the latest insights we've been sharing on LinkedIn
December 5, 2025
RE at the 2026 J. P. Morgan Healthcare Conference
by Real Endpoints
Real Endpoints will be meeting at JP Morgan in January with a variety of folks on these and other issues – and would love to sit down with you as well. We can fill you in on what we see as the implications of policy and payer changes on coverage, reimbursement, and patient support; what we’re expecting for 2026; and discuss the specific topics you’re most concerned about.
read full article >June 7, 2025
Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders.
by Real Endpoints
Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders. Thing is these implications could also easily apply to any number of drugs in other competitive disease spaces, where there is high budget impact and more than a little uncertainty about clinical benefit.
LinkedIn >
June 5, 2025
Key Market Access Insights from Sanofi’s $9B Blueprint Deal
by Real Endpoints
Sanofi’s $9B acquisition of Blueprint Medicines brings a welcome burst of heat to biotech’s long dealmaking winter. And it offers a few clear reminders about how access and reimbursement shape commercial value today.
LinkedIn >
May 28, 2025
Real Endpoints’ CEO at Swiss HLG Conference
by Real Endpoints
Thanks to the team at SwissHLG for inviting our CEO Jeff Berkowitz to discuss how early stage biotechs - and the investors who fund them - should invest in critical market access capabilities to drive commercial success.
LinkedIn >
May 20, 2025
Supporting Patients Amid Rising Cost-Sharing Trends
by Real Endpoints
President Trump today signed an Executive order that, despite the pomp and circumstance, provided little to no detail on how it would be carried out. As expected, the order highlights Trump’s intent to use a “Most Favored Nation” strategy, in which U.S. prices will be tied to the lowest drug prices paid by developed countries.
LinkedIn >